Xiaolei Xun
About Xiaolei Xun
Xiaolei Xun is the Director at BeiGene in Shanghai, China, with over a decade of experience in the pharmaceutical and biotechnology industry, including previous roles at Novartis and Fudan University.
Director at BeiGene
Xiaolei Xun serves as Director at BeiGene, based in Shanghai, China. In this role, Xun oversees various strategic and operational initiatives, leveraging over a decade of experience in the pharmaceutical and biotechnology industry. His expertise in biostatistics and biometrics plays a crucial role in the company's ongoing projects and developments.
Previous Roles at BeiGene
Before becoming Director, Xiaolei Xun held the position of Associate Director at BeiGene from 2020 to 2021. During this period, he contributed significantly to the company's projects, applying his extensive background in statistical methodologies to enhance operational efficiencies and research outcomes.
Experience at Novartis
Xiaolei Xun's career includes multiple roles at Novartis in Shanghai. He began as a Sr Biometrician from 2012 to 2013 before progressing to Sr Biometrician II, Principal Biometrician, and finally Statistical Methodologist. His work involved developing and applying biostatistics and biometrics methods crucial for pharmaceutical research and development.
Academic Background and Experience
Xiaolei Xun was a Visiting Associate Professor at Fudan University from 2017 to 2020. This academic experience enriched his understanding of biostatistics applications, allowing him to bring a well-rounded perspective to his industry roles. He holds a degree from Texas A&M University, where he studied from 2007 to 2012, and also studied at Zhejiang University.
Transition to Leadership in Industry
Xiaolei Xun transitioned from his academic role at Fudan University to a leadership position in the industry. His extensive experience in both settings has given him unique insights into biostatistics applications, making him a valuable asset to BeiGene. His career trajectory shows a consistent focus on leveraging statistical expertise to drive innovation in the pharmaceutical and biotechnology sectors.